GRI BIO Faces Delisting Concerns
Ticker: GRI · Form: 8-K · Filed: Jul 8, 2024 · CIK: 1824293
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
GRI BIO might get delisted, stock watch.
AI Summary
GRI BIO, Inc. (formerly Vallon Pharmaceuticals, Inc.) filed an 8-K on July 8, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company, incorporated in Delaware, is in the pharmaceutical preparations industry and has its principal executive offices in La Jolla, CA.
Why It Matters
This filing indicates potential issues with GRI BIO's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event for a publicly traded company.
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- July 2, 2024 (date) — Earliest event reported date
- July 8, 2024 (date) — Filing date
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific listing rule or standard has GRI BIO, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that GRI BIO, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the effective date of the delisting notice?
The filing reports the earliest event date as July 2, 2024, and the filing date as July 8, 2024. The specific effective date of the delisting action is not detailed in this initial report.
Has GRI BIO, Inc. previously changed its name?
Yes, GRI BIO, Inc. was formerly known as Vallon Pharmaceuticals, Inc., with a date of name change on September 10, 2020.
What is the primary business of GRI BIO, Inc.?
GRI BIO, Inc. is in the Pharmaceutical Preparations industry, with Standard Industrial Classification code 2834.
Where are GRI BIO, Inc.'s principal executive offices located?
GRI BIO, Inc.'s principal executive offices are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
Filing Stats: 543 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-07-08 09:07:05
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20240702.htm (8-K) — 24KB
- ex991_pressreleasenasdaqco.htm (EX-99.1) — 10KB
- image_0.jpg (GRAPHIC) — 37KB
- val-20240702_g1.jpg (GRAPHIC) — 16KB
- val-20240702_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000078.txt ( ) — 243KB
- val-20240702.xsd (EX-101.SCH) — 2KB
- val-20240702_lab.xml (EX-101.LAB) — 23KB
- val-20240702_pre.xml (EX-101.PRE) — 13KB
- val-20240702_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 2, 2024, GRI Bio, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the equity deficiency under Listing Rule 5550(b), which the Company previously reported on in its Current Reports on Form 8-K filed on November 24, 2023 and May 22, 2024, has been cured, and that the Company is now in compliance with all applicable continued listing standards. As a result, the Company will no longer appear before the Nasdaq Hearings Panel with respect to this prior deficiency.
01 Other Events
Item 8.01 Other Events. On July 8, 2024, the Company issued a press release announcing that it is now in compliance with all applicable Nasdaq continued listing standards. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by GRI Bio, Inc., dated July 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 8, 2024 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer